Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

GenXys Health Care Systems Advances Effort to Reduce Adverse Drug Reactions, the 4th Leading Cause of Death in No. America

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

GenXys Health Care Systems the global leader in precision prescribing software and embedded pharmacogenetic data, today joins the American Society of Pharmacovigilance in raising awareness of adverse drug reactions (ADRs) on National Adverse Drug Event Awareness Day.

With ADRs being the fourth leading cause of death in North America (excluding COVID-19), GenXys is working to reduce ADRs by advancing precision medicine, improving patient safety and treatment response, and reducing health care costs.

There are 46 million ADRs leading to 1.3 million emergency room visits each year in the United States alone. ADRs include medication errors, medication side effects, allergic reactions to medications, and overdoses, and they add $136 billion in U.S. health care costs each year. According to the Agency for Healthcare Quality and Research (AHRQ), adverse drug events are the costliest and most preventable hospital-acquired condition.

Genetic variants affect the efficacy, dosage, and safety of 50 percent of all commonly prescribed medications. In fact, 97% of the population has at least one pharmacogenetic variant that influences how medication is metabolized by the body.

Pharmacogenetic testing can help inform medication decisions that avoid “trial and error” prescribing. GenXys’ clinical decision support software, which interprets data from pharmacogenetic testing, is used by major insurance providers, health systems, and pharmacies across North America. GenXys’ software can ensure that medication is much more likely to work from the start, identifying the right medication and the right dose for each patient.

“The GenXys team is driven by a mission to make every prescription better to avoid ADRs,” says Karl Pringle, CEO of GenXys Health Care Systems. “When it comes to medicine, one size does not fit all. Our precision prescribing software with pharmacogenetic interpretation solutions helps personalize drug selection to increase effectiveness, eliminate side effects, and reduce health care costs.”

With COVID testing abating, genetic labs are reorienting their testing to high growth and wide applicability areas such as pharmacogenetics. GenXys is seeing a significant uptick in proposal requests and inquiries, and the company recently added several new customers for its clinical decision support software with embedded pharmacogenetics. GenXys is working with innovative U.S.-based CLIA and/or CAP labs and associated health clinics, as well as a focused pharmacy network, which is incorporating pharmacogenetics into patient care.

For more information on ADRs and their impact on health care, visit here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine